S c i e n t i f i c Ι C u l t u r a l E v e n t s & P u b l i c a t i o n s Τ 210 7240039 F 210 7240139 E [email protected] www.scep.gr
h t t p : / / h e l l e n i c - i m m u n o o n c o l o g y . g r / Organized by Hellenic Society of Immuno-Oncology
November 29 - December 1 . 2018 Royal Olympic Hotel Athens | Greece
Symposium on Advances in
Cancer Immunology andImmunotherapy
S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y
03
Thursday, November 29th, 201814:45-15:00 Welcome
SESSION 1: Overcoming immune suppression15:00-15:30 The role of Myeloid-derived suppressor cells in tumor immune evasion V. Bronte (IT) 15:30-16:00 Immune suppression in Melanoma V. Umansky (GE) 16:00-16:30 Interplay between cellular senescence and cancer D. Kletsas (GR)
Plenary lecture16:30-17:15 Tregs T. Whiteside (USA)
17:15-17:45 Co f fee Break
SESSION 2: The role of innate immunity in cancer
17:45-18:15 The regulatory role of chemokines in cancer progression N. Karin (IL) 18:15-18:45 Toll-like receptors T. Bagratuni (GR) 18:45-19:15 Regulation of tumor metastases by NK cells O. Mandelboim (GE)
Plenary lecture
19:15-20:00 Cancer Stem Cells In breast carcinomas F. Cavallo (IT)
20:00 Welcome reception
Friday, November 30th, 2018 SESSION 3: Monitoring of immunomodulatory mechanisms09:30-10:00 The emerging role of exosomes T.L. Whiteside (USA) 10:00-10:30 Proteomics-proteogenomics T. Katsila (GR) 10:30-11:00 Lipid metabolism and anticancer immunity G. Adema (NL) 11:00-11:30 TBA P. Verginis (GR)
Plenary lecture11:30-12:15 The immunomodulatory role of microRNAs during the process of tumor immune evasion B. Seliger (GE)
12:15-12:45 Co f fee b reak
12:45-14:30 Short oral presentations-research
14:30-15:30 Lunch
SESSION 4: Special session on combinational treatment (I) 15:30-16:00 Targetingstrategiestoenhancetheeffectivenessofimmunotherapies Ed. C. Lavelle (IE) 16:00-16:30 Interplay of radiation and immunotherapy TBA 16:30-17:00 Combination of anti-PD1/PDL1 with newer immunomodulatory agents (newer ICI, IDO, TGF-b CD40 agonists, IL-15...) TBA 17:00-17:30 Immune checkpoint inhibitors and chemotherapy: update of the recently published studies TBD
17:30-18:00 Co f fee b reak
Dear Colleagues,
The Hellenic Society of Immuno-Oncology organizes the 4th Symposium on Advances in Cancer Immunology and
Immunotherapy, which will be held on November 29 - December 1, 2018, in Athens, Greece.
The meeting aim to bring together many of the leading researchers and clinicians in Europe and the US to report on
most recent advances made in cancer immunology and immunotherapy. Our main objectives are to gather, share
and exchange experiences and ideas; translate and extend this knowledge to the clinic; promote interactions between
speakers and participants and encourage stimulating discussions; provide network opportunities and stimulate new
collaborations. This year, we have introduced a new element, as all young researchers that will participate in the poster
sessions will be additionally given the opportunity to present the highlights of their work as a short oral presentation
(5 - 10 minutes each).
OnbehalfoftheOrganizingandScientificCommittees,wearepleasedtoinviteyoutoparticipate.Wehopethatyouwill
share this event within your community and invite your colleagues and students to take part as well.
WeverymuchlookforwardseeingyouthisNovemberinAthens.
Best regards,
The Organizing Committee Chairs
Athanasios Kotsakis, MD, PhD,
Associate Professor of Medical Oncology,
Director of Dpt of Medical Oncology,
University Hospital of Larisa,
Thessaly, Greece
Ourania Tsitsilonis, MD, PhD,
Associate Professor of Immunology,
Department of Biology,
National & Kapodistrian
University of Athens, Greece
Nikolaos Kentepozidis, MD, PhD,
Medical Oncologist,
Head of Oncology Clinic,
251 General Airforce Hospital,
Athens, Greece
Constantin N. Baxevanis, PhD,
ScientificDirector,
Cancer Immunology and
Immunotherapy Center “Agios Savvas”
Hospital, Athens, Greece
S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y
04 05
SESSION 5: Special session on combinational treatment (II)18:00-18:30 ICI and targeted therapies N. Karachaliou (ES) 18:30-19:00 Immunotherapy in earlier stages A. Marabelle - TBC
Plenary lecture19:00-19:45 Precision Medicine in Cancer C. Le Tourneau (FR)
Saturday, December 1st, 2018 SESSION 6: Biomarkers for Immunotherapy09:30-10:00 Advances on biomarkers for immunotherapy beyond PD-L1 expression TBD 10:00-10:30 Activatedintegrinsrevealfunctionalantigen-specificTcells C. Gouttefangeas (DE) 10:30-11:00 Using genomic signatures as predictive marker for immunotherapy C. Denkert - TBC 11:00-11:30 Tumor-associated and non tumor associated microbiota TBA
11:30-11:45 Co f fee b reak
Plenary lecture11:45-12:30 Immune contexture as a prognostic biomarker H. W. Fridman (FR)
12:30-13:45 Short oral presentations-clinical 13:45-15:00 Lunch b reak
SESSION 7: Immunotherapy (II)15:00-15:30 Adoptive Cell therapy in solid tumors T.H. Borch (DK) 15:30-16:00 Therapeuticadvancesofimmunotherapyinthefieldof mesenchymal tumors D. Heymann (UK) 16:00-16:30 Immunotherapy in GU Cancer N. Pistamaltzian (GR) 16:30-17:00 Immunotherapy in Blood Cancers G. Vassilopoulos (GR)
17:00-17:30 Co f fee b reak
Plenary lecture17:30-18:15 Intratumoral heterogeneity detected via next generation sequencing of T cell receptors R. Offringa (GE)
SESSION 8: Immunotherapy (III)18:15-18:45 Current status of immunotherapy in head and neck cancer A. Argiris (GR) 18:45-19:15 Whatisnewinimmunotherapyformelanoma M. Neagu (RO) 19:15-19:45 Overcoming primary and acquired resistance in immune checkpoint inhibitors C. N. Baxevanis (GR) 19:45-20:15 Management of toxicities A. Koumarianou (GR)
20:15-20:45 Awards - Closing remarks
CALL FOR ABSTRACTS 2018TheOrganizingandScientificCommitteesofthe4th Symposium on Advances in Cancer Immunology and Immunotherapyinvitesubmissionofscientificabstractsforshortoralandposterpresentations.
AbstractsmustbesubmittedinEnglishthroughtheSymposiumofficialwebsite: www.hellenic-immunooncology.gr
Abstractswillbeselectedonscientificmerit.Abstractsubmissionstarts on August 6th, 2018
PleasesubmityourabstractviatherelevantformontheSymposiumWebsite. Submissions by fax or post will NOT be accepted.
Abstract submission will close at 24:00 hours Central European Time (CET) on Sunday, October 28th, 2018.
NotificationofacceptancewillbemadebyNovember 12th, 2018.
S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y
06
NOTESNOTES
General InformationO r g a n i z e d b y Hellenic Society of Immuno-Oncology (HeSIO) G. Theologou 5, Τ.Κ.11474,Athens,Greece www.hellenic-immunooncology.gr
D a t e s November 29th - December 1st. 2018
W e b s i t e : http://hellenic-immunooncology.gr
S y m p o s i u m V e n u e Royal Olympic Hotel, Athens 28-34,AthanasiouDiakouStr.,11743,Athens,GREECE Tel.:+3021092.88.400 Fax:+3021092.33.317 E-mail: [email protected]
P r i c e p e r D e l e g a t e Registration Fee Undergraduate students and postgraduate students 0€ PhD students 0€ Post-docs and MD 200€
C e r t i f i c a t e o f A t t e n d a n c e Based on the latest circular of the National Drug Organization the Symposium is required to use an attendance trackingsystem.Allregisteredparticipantswillreceivenamebadges,whichtheyarekindlyrequestedtowearatall times. Each badge will have a barcode for monitoring the hours of attendance. By the end of the symposium a certificatewillbegiventothosewhohaveattendedatleast60%ofthetotalhoursoftheScientificProgram.
O f f i c i a l L a n g u a g e EnglishistheofficiallanguageoftheSymposium.
S y m p o s i u m S e c r e t a r i a t
Sc ien t i f i c Ι Cu l tura l Events and Pub l i ca t ions T+302107240039F+302107240139E [email protected] www.scep.gr